Navigation Links
Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
Date:6/27/2011

ibutor to lung carcinogenesis.  In a phase 2 clinical trial patients with recurrent, metastatic NSCLC having received at least one prior chemotherapy regimen were given 5-azacitidine (5AC) and entinostat. The trial showed that the combination of 5AC and entinostat is generally well tolerated and demonstrated major objective responses. Through biomarker analyses investigators identified a subset of patients where a greater clinical benefit was observed.  This subset consisted of patients with more methylated alleles and who experienced decreasing methylation during the first cycle of entinostat and 5AC.  This study is being sponsored by the NCI under a Cooperative Research and Development Agreement with Syndax.

"These exciting biomarker data provide new insight and a path forward to selecting patients with NSCLC for whom the entinostat and 5AC combination may be particularly beneficial," added  Dr. Horobin.  

The data from the entinostat and 5AC combination will be presented at the World Conference on Lung Cancer: Date:

Tuesday, July 5:Time:

12:15 PM - 2:00 PMSession info:

P2.257Title:

Biomarker Development for a Phase II Study of Combination Epigenetic Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)Room:

Exhibition Hall About EntinostatSyndax's lead product entinostat has been studied in more than 600 cancer patients where objective tumor responses have been observed in both solid and hematologic malignancies. Entinostat's established safety profile as both a single agent and in combination with a number of commercially available targeted therapies differentiates it from other histone deacetylase (HDAC) inhibitors. Having shown potential in breast and lung cancer, entinostat is moving toward pivotal clinical testing. It is a novel inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression. This aberrant gene expression
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
2. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
3. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
4. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
5. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
6. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
7. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
8. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
9. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
10. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
11. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
(Date:12/25/2014)... updated its blog to provide professional shopping tips on wedding and ... LunaDress.co.uk come with big discounts, up to 80 percent off. , ... to be a most exciting memory and can show off a ... a wedding. On the updated fashion blog, ladies can now find ... day . , Going out with friends to a party is ...
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... 2007) Lower muscle mass and an increase in body ... exercise is a proven way to prevent the loss of ... Mark Tarnopolsky shows that taking a combination of creatine monohydrate ... exercise training provides even greater benefits. , The ...
... 2 Speaker Nancy Pelosi,released the following statement ... The Speaker was presented the National Breast,Cancer Coalition,s ... York City last,night: "National Breast Cancer Awareness ... and to recommit ourselves to advancing prevention, improving,treatments, ...
... imagine iPhones, laptops and flash drives. But more ... a newly updated inventory of nanotechnology consumer products ... and health products. , Maintained by the ... inventory includes Head NanoTitanium Tennis Racquets, Eddie Bauer ...
... is a statement,by Linda A. Suydam, D.P.A., president ... to inaccurate and misleading media reports,surrounding the U.S. ... Nonprescription Drugs Advisory Committee and Pediatric Advisory,Committee scheduled ... the makers of pediatric, over-the-counter cough and cold,medicines ...
... WASHINGTON, Oct. 2 Speaker Nancy Pelosi and,Senate Majority ... sending President Bush the Children,s Health Insurance,Program (CHIP) legislation:, ... a bipartisan bill,to insure 10 million of our nation,s ... American people that the President will sign the bill ...
... Offer Both Suspension and Tablet Forms, PRINCETON, N.J., ... subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that RLL ... Administration (U.S. FDA) to manufacture and market Clarithromycin for,Oral ... Ranbaxy is the first,company to have been granted a ...
Cached Medicine News:Health News:Nanotechnology: not just for geeks 2Health News:Statement from the Consumer Healthcare Products Association on the Safety of Pediatric Over-the-Counter Medicines 2Health News:Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP 2
Suitable for mild to moderate ACL and/or PCL, MCL and LCL instabilities, this neoprene brace with extended hinge bars is an ideal intermediate-level product that can be used in sporting activities. C...
Provides range-of-motion control for both flexion and extension along with a drop lock feature...
Provides comfortable compression, support and immobilization for the knee...
Dynamic brace that provides a low load, prolonged stretch to the connective tissue around the joint using an adjustment hinge with a built-in tension spring...
Medicine Products: